InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,738.00
(
0.31%
)
Dow Jones
39,512.84
(
0.00%
)
Brent Oil
83.08
(
0.84%
)
Bitcoin
62,691.00
(
2.02%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 358

Friday, 09/21/2018 11:40:45 AM

Friday, September 21, 2018 11:40:45 AM

Post# of 438
MTEM is an early stage clinical oncology biotech with some gravitas in the form of important partnerships with AFMD & Takeda.

The lead program is in a Ph1-b study in non-Hodgkins Lymphoma (NHL). Some extension 1-b results are due 12/18. The Ph1-a results were presented at ASCO and were uninspiring.

MTEM has a research collaboration with AFMD to identify antibodies for MTEM's targets using the ABsieve tool.

Perhaps this approach lead to the recently announced partnership with Takeda. This partnership came with a $30mn upfront payment.

With this upfront payment, MTEM has an operational runway thru 2020.

I will not be interested in the stock until after Ph1-b NHL results are announced.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up